Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0N8UY
|
||||
| Former ID |
DIB010148
|
||||
| Drug Name |
LY-686017
|
||||
| Synonyms |
NK1 antagonist (anxiety/alcoholism), Eli Lilly
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Alcohol use disorders [ICD9: 303; ICD10:F10.2] | Phase 2 | [1] | ||
| Company |
Eli Lilly & Co
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C28H16ClF6N5O
|
||||
| Canonical SMILES |
c1(c(n(nn1)Cc1cc(C(F)(F)F)cc(C(F)(F)F)c1)c1ccncc1)c1c(C<br />(=O)c2c(Cl)cccc2)cccn1
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Substance-P receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Measles | |||||
| PANTHER Pathway | CCKR signaling map ST | ||||
| Reactome | G alpha (q) signalling events | ||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Spinal Cord Injury | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00191022) Comparison of LY686017 With a Marketed Drug in the Treatment of Social Anxiety Disorder. U.S. National Institutes of Health. | ||||
| REF 2 | Stress-related neuropeptides and alcoholism: CRH, NPY and beyond. Alcohol. 2009 November; 43(7): 491-498. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.